Clinical Validation of the Intermediate-risk Non–muscle-invasive Bladder Cancer Scoring System and Substratification Model Proposed by the International Bladder Cancer Group: A Multicenter Young Academic Urologists Urothelial Working Group CollaborationFrancesco Soria, Paolo Gontero, David D‘Andrea et al.|European Urology Oncology|2024Cited by 32
The Role of Mitomycin C in Intermediate-risk Non–muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysisPietro Scilipoti, Marco Moschini, Aleksander Ślusarczyk et al.|European Urology Oncology|2024Cited by 29
Implications for diagnosis and treatment strategies in non-muscle invasive bladder cancer with variant histology: a systematic reviewGiuseppe Basile, Roberto Carando, Mario de Angelis et al.|Minerva Urology and Nephrology|2023Cited by 18
Compared Efficacy of Adjuvant Intravesical BCG-TICE vs. BCG-RIVM for High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC): A Propensity Score Matched AnalysisFrancesco Del Giudice, Gian Maria Busetto, Rocco Simone Flammia et al.|Cancers|2022Cited by 17
Bladder-sparing strategies in patients with clinically localized muscle-invasive bladder cancerMario de Angelis, Marco Moschini, Giuseppe Basile et al.|Current Opinion in Urology|2023Cited by 17